Weighted Average Number of Shares Outstanding, Basic of CITIUS ONCOLOGY, INC. from 30 Sep 2021 to 31 Dec 2025
- Taxonomy & unit
- us-gaap: shares
- Description
- Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
- Summary
-
CITIUS ONCOLOGY, INC. quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 30 Sep 2021 to 31 Dec 2025.
- CITIUS ONCOLOGY, INC. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 31 Dec 2025 was 87,462,385, a 22% increase year-over-year.
- CITIUS ONCOLOGY, INC. annual Weighted Average Number of Shares Outstanding, Basic for 2025 was 73,267,969, a 7.7% increase from 2024.
- CITIUS ONCOLOGY, INC. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 68,053,607, a 931% increase from 2023.
- CITIUS ONCOLOGY, INC. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 6,600,000, a 392% increase from 2022.
- Source SEC data
- View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)
CITIUS ONCOLOGY, INC. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 87,462,385 | +15,909,983 | +22% | 01 Oct 2025 | 31 Dec 2025 | 10-Q | 13 Feb 2026 | 2026 | Q1 | |
| Q3 2025 | 73,267,969 | +5,214,362 | +7.7% | 01 Jul 2025 | 30 Sep 2025 | 10-K | 23 Dec 2025 | 2025 | FY | |
| Q2 2025 | 71,552,402 | +4,052,402 | +6% | 01 Apr 2025 | 30 Jun 2025 | 10-Q | 12 Aug 2025 | 2025 | Q3 | |
| Q1 2025 | 71,552,402 | +4,052,402 | +6% | 01 Jan 2025 | 31 Mar 2025 | 10-Q | 14 May 2025 | 2025 | Q2 | |
| Q4 2024 | 71,552,402 | +4,052,402 | +6% | 01 Oct 2024 | 31 Dec 2024 | 10-Q | 13 Feb 2026 | 2026 | Q1 | |
| Q3 2024 | 68,053,607 | +61,453,607 | +931% | 01 Jul 2024 | 30 Sep 2024 | 10-K | 23 Dec 2025 | 2025 | FY | |
| Q2 2024 | 67,500,000 | +60,900,000 | +923% | 01 Apr 2024 | 30 Jun 2024 | 10-Q | 12 Aug 2025 | 2025 | Q3 | |
| Q1 2024 | 67,500,000 | +60,900,000 | +923% | 01 Jan 2024 | 31 Mar 2024 | 10-Q | 14 May 2025 | 2025 | Q2 | |
| Q4 2023 | 67,500,000 | +66,158,242 | +4931% | 01 Oct 2023 | 31 Dec 2023 | 10-Q | 14 Feb 2025 | 2025 | Q1 | |
| Q3 2023 | 6,600,000 | +5,100,000 | +340% | 01 Jul 2023 | 30 Sep 2023 | 10-Q | 20 Nov 2023 | 2023 | Q3 | |
| Q2 2023 | 6,600,000 | +5,100,000 | +340% | 01 Apr 2023 | 30 Jun 2023 | 10-Q | 09 Aug 2024 | 2024 | Q2 | |
| Q1 2023 | 6,600,000 | +4,875,000 | +283% | 01 Jan 2023 | 31 Mar 2023 | 10-Q | 20 May 2024 | 2024 | Q1 | |
| Q4 2022 | 1,341,758 | 01 Oct 2022 | 31 Dec 2022 | 10-K | 16 Apr 2024 | 2023 | FY | |||
| Q3 2022 | 1,500,000 | 0 | 0% | 01 Jul 2022 | 30 Sep 2022 | 10-Q | 20 Nov 2023 | 2023 | Q3 | |
| Q2 2022 | 1,500,000 | 01 Apr 2022 | 30 Jun 2022 | 10-Q | 16 Aug 2023 | 2023 | Q2 | |||
| Q1 2022 | 1,725,000 | 01 Jan 2022 | 31 Mar 2022 | 10-Q | 15 May 2023 | 2023 | Q1 | |||
| Q3 2021 | 1,500,000 | 01 Jul 2021 | 30 Sep 2021 | 10-Q | 28 Nov 2022 | 2022 | Q3 |
CITIUS ONCOLOGY, INC. Annual Weighted Average Number of Shares Outstanding, Basic (shares)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | 73,267,969 | +5,214,362 | +7.7% | 01 Oct 2024 | 30 Sep 2025 | 10-K | 23 Dec 2025 | 2025 | FY |
| 2024 | 68,053,607 | +61,453,607 | +931% | 01 Oct 2023 | 30 Sep 2024 | 10-K | 23 Dec 2025 | 2025 | FY |
| 2023 | 6,600,000 | +5,258,242 | +392% | 01 Jan 2023 | 31 Dec 2023 | 10-K | 16 Apr 2024 | 2023 | FY |
| 2022 | 1,341,758 | 01 Jan 2022 | 31 Dec 2022 | 10-K | 16 Apr 2024 | 2023 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.